Biocon Ltd
NSE:BIOCON
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
233.1
391.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Biocon Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | IN |
Market Cap | 423.4B INR |
Net Margin |
10%
|
Country | FR |
Market Cap | 6T USD |
Net Margin |
-21 040%
|
Country | US |
Market Cap | 320.1B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 150.5B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 120.4B USD |
Net Margin |
-5%
|
Country | US |
Market Cap | 113.8B USD |
Net Margin |
0%
|
Country | US |
Market Cap | 94.1B EUR |
Net Margin |
-392%
|
Country | AU |
Market Cap | 135.4B AUD |
Net Margin |
18%
|
Country | US |
Market Cap | 82.9B USD |
Net Margin |
34%
|
Country | US |
Market Cap | 39.3B EUR |
Net Margin |
-33%
|
Country | NL |
Market Cap | 34.5B EUR |
Net Margin |
-14%
|
Biocon Ltd
Glance View
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Biocon Ltd's most recent financial statements, the company has Net Margin of 9.7%.